tetracenomycin B₁

• 分子结构分类: 有机化合物 - 苯类化合物 - 并四苯
• 英文名称: tetracenomycin B₁
• 英文别名: Tetracenomycin B1；1,8,11-trihydroxy-3-methoxy-10-methyltetracene-5,12-dione
• 化学式: C₂₀H₁₄O₆
• 分子量: 350.328
• InChiKey: CXOLVKMMHKZPPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (Z)-(1,3-dimethoxybuta-1,3-dienyloxy)trimethylsilane 、 Acetic acid 10-hydroxy-4-methyl-5,8-dioxo-5,8-dihydro-anthracen-2-yl ester 生成 tetracenomycin B₁
  参考文献：
  名称：

  Synthesis of tetracenomycins

  摘要：

  Tetracenomycins D, A2, B1 and B2 (2)-(5) have been synthesised for the first time, by an efficient, regioselective sequence based on cycloaddition methodology; the ambiguity that existed for tetracenomycins B1 and B2 has thereby been resolved in favour of structures (4a) and (5b) respectively.

  DOI：

  10.1016/s0040-4039(00)61155-3

文献信息

• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
• Synthesis of tetracenomycins
  作者：Donald W. Cameron、Pauline J. de Bruyn

  DOI：10.1016/s0040-4039(00)61155-3

  日期：1992.9

  Tetracenomycins D, A2, B1 and B2 (2)-(5) have been synthesised for the first time, by an efficient, regioselective sequence based on cycloaddition methodology; the ambiguity that existed for tetracenomycins B1 and B2 has thereby been resolved in favour of structures (4a) and (5b) respectively.